SE8703625D0 - New medical use - Google Patents

New medical use

Info

Publication number
SE8703625D0
SE8703625D0 SE8703625A SE8703625A SE8703625D0 SE 8703625 D0 SE8703625 D0 SE 8703625D0 SE 8703625 A SE8703625 A SE 8703625A SE 8703625 A SE8703625 A SE 8703625A SE 8703625 D0 SE8703625 D0 SE 8703625D0
Authority
SE
Sweden
Prior art keywords
medical use
new medical
igf
insulin
mammals
Prior art date
Application number
SE8703625A
Other languages
English (en)
Swedish (sv)
Inventor
K Fryklund
H A Hansson
M Kanje
A Skottner
Original Assignee
Kabivitrum Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabivitrum Ab filed Critical Kabivitrum Ab
Priority to SE8703625A priority Critical patent/SE8703625D0/xx
Publication of SE8703625D0 publication Critical patent/SE8703625D0/xx
Priority to US07/245,146 priority patent/US5068224A/en
Priority to ES88850306T priority patent/ES2043890T3/es
Priority to EP88850306A priority patent/EP0308386B1/en
Priority to AT88850306T priority patent/ATE82507T1/de
Priority to DE8888850306T priority patent/DE3876052T2/de
Priority to GR930400325T priority patent/GR3007092T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SE8703625A 1987-09-18 1987-09-18 New medical use SE8703625D0 (sv)

Priority Applications (7)

Application Number Priority Date Filing Date Title
SE8703625A SE8703625D0 (sv) 1987-09-18 1987-09-18 New medical use
US07/245,146 US5068224A (en) 1987-09-18 1988-09-16 Method of improving regeneration of transfected peripheral nerves using igf-1
ES88850306T ES2043890T3 (es) 1987-09-18 1988-09-16 Nuevo uso medico.
EP88850306A EP0308386B1 (en) 1987-09-18 1988-09-16 New medical use
AT88850306T ATE82507T1 (de) 1987-09-18 1988-09-16 Medizinische verwendung.
DE8888850306T DE3876052T2 (de) 1987-09-18 1988-09-16 Medizinische verwendung.
GR930400325T GR3007092T3 (https=) 1987-09-18 1993-02-17

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8703625A SE8703625D0 (sv) 1987-09-18 1987-09-18 New medical use

Publications (1)

Publication Number Publication Date
SE8703625D0 true SE8703625D0 (sv) 1987-09-18

Family

ID=20369616

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8703625A SE8703625D0 (sv) 1987-09-18 1987-09-18 New medical use

Country Status (7)

Country Link
US (1) US5068224A (https=)
EP (1) EP0308386B1 (https=)
AT (1) ATE82507T1 (https=)
DE (1) DE3876052T2 (https=)
ES (1) ES2043890T3 (https=)
GR (1) GR3007092T3 (https=)
SE (1) SE8703625D0 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166317A (en) * 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US6440928B1 (en) 1988-12-06 2002-08-27 Colorado State University Research Foundation Method for treating diabetic neuropathy with NGF
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6693076B1 (en) 1989-06-05 2004-02-17 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
US6723699B1 (en) 1989-06-05 2004-04-20 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
ZA9010332B (en) * 1989-12-22 1991-08-28 Ciba Geigy Method of reducing or preventing adverse effect of steroid therapy and compositions therefor
AU637199B2 (en) * 1990-02-13 1993-05-20 Novozymes Biopharma Dk A/S Method for treating intestinal diseases
DE69129267T2 (de) * 1990-02-13 1998-09-10 Gropep Pty. Ltd., Adelaide Methode zur behandlung intestinaler krankheiten
US5679771A (en) * 1990-02-13 1997-10-21 Gropep Pty. Ltd. Method for treating intestinal diseases
US5545719A (en) * 1990-05-01 1996-08-13 Neuromedica, Inc. Nerve growth peptides
SE9100099D0 (sv) * 1991-01-11 1991-01-11 Kabi Pharmacia Ab Use of growth factor
EP0597033B1 (en) * 1991-08-01 1997-04-09 Genentech, Inc. Igf-1 to improve the neural condition
US5861373A (en) * 1991-08-01 1999-01-19 Genentech, Inc IGF-1 to improve the neural condition
US6310040B1 (en) * 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
EP0615452A4 (en) * 1991-11-25 1995-07-12 Inst Molecular Biology Inc MEDICINE SERVING THE PROMOTION OF THE GROWTH OF A NERVE IN MAMMALS.
IT1254706B (it) 1991-12-23 1995-10-09 Fidia Spa Uso terapeutico del ganglioside gm1 nel trattamento del danno al midollo spinale
SE9201573D0 (sv) * 1992-05-19 1992-05-19 Kabi Pharmacia Ab Use of igf-1
US5420112A (en) * 1992-06-12 1995-05-30 Lewis; Michael E. Prevention and treatment of peripheral neuropathy
HU217543B (hu) * 1992-06-12 2000-02-28 Albert Einstein College Of Medicine Of Yeshiva University Eljárás perifériás neuropátia kezelésére és megelőzésére alkalmas gyógyászati készítmények előállítására, valamint inzulinszerű növekedési faktor I-et és kemoterápiás szert tartalmazó gyógyászati készítmények
US20070078089A1 (en) * 1992-07-06 2007-04-05 Ishii Douglas N Method for effecting changes in the central nervous system by administration of IGF-I or IGF-II
SE9301667D0 (sv) * 1993-05-14 1993-05-14 Kabi Pharmacia Ab New use
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
SE9402370D0 (sv) 1994-07-04 1994-07-04 Pharmacia Ab Use of IGF-I
US5834029A (en) * 1994-07-20 1998-11-10 Cytotherapeutics, Inc. Nerve guidance channel containing bioartificial three-dimensional hydrogel extracellular matrix derivatized with cell adhesive peptide fragment
US5565428A (en) * 1995-05-22 1996-10-15 Genentech, Inc. Method of administration of IGF-I
US5741776A (en) * 1995-05-22 1998-04-21 Genentech, Inc. Method of administration of IGF-I
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US5916569A (en) * 1997-03-26 1999-06-29 E. Martin Spencer Human erectile dysfunction and methods of treatment
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6121416A (en) 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7687039B2 (en) * 1998-10-28 2010-03-30 Covaris, Inc. Methods and systems for modulating acoustic energy delivery
AU762351B2 (en) * 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
GB0011278D0 (en) 2000-05-10 2000-06-28 Univ London Repair of nerve damage
ATE389416T1 (de) * 2000-05-16 2008-04-15 Genentech Inc Behandlung von knorpelerkrankungen
ATE463252T1 (de) * 2000-08-29 2010-04-15 Aurogen Inc Methode zur behandlung des zentralnervensystems durch applikation von strukturanaloga von igf
CN100439397C (zh) * 2001-02-09 2008-12-03 基因技术股份有限公司 Igf-1的结晶
EP1427407A4 (en) * 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
ES2387562T3 (es) 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
EP1401808B1 (en) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe analogs and peptidomimetics
US20070004641A1 (en) * 2001-05-24 2007-01-04 Neuren Pharmaceuticals Limited Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
GB0202906D0 (en) * 2002-02-07 2002-03-27 Univ London Prevention of myocardial damage
JP3977162B2 (ja) * 2002-06-21 2007-09-19 株式会社バンダイナムコゲームス キャラクタ情報管理装置、プログラム及び情報記憶媒体
CN1753667A (zh) * 2003-05-27 2006-03-29 三得利株式会社 具有植物神经调节作用的组合物及其使用方法
JP2008511838A (ja) * 2004-08-30 2008-04-17 テルシカ・インク インシュリン様成長因子欠乏疾患の診断及び治療のための方法及び装置
WO2006097682A1 (en) * 2005-03-18 2006-09-21 Ucl Business Plc Mechano growth factor peptides and their use
AR059088A1 (es) * 2006-01-20 2008-03-12 Genzyme Corp Administracion intraventricular de una proteina para esclerosis lateral amiotrofica
WO2012102100A1 (ja) 2011-01-26 2012-08-02 雪印メグミルク株式会社 感覚改善剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes

Also Published As

Publication number Publication date
ATE82507T1 (de) 1992-12-15
EP0308386B1 (en) 1992-11-19
US5068224A (en) 1991-11-26
DE3876052T2 (de) 1993-03-25
ES2043890T3 (es) 1994-01-01
GR3007092T3 (https=) 1993-07-30
DE3876052D1 (de) 1992-12-24
EP0308386A1 (en) 1989-03-22

Similar Documents

Publication Publication Date Title
SE8703625D0 (sv) New medical use
FI875533A0 (fi) Insulinpreparat foer non-parenteral dosering.
ATE204176T1 (de) Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven
EP0363415A4 (en) Compounds for the treatment of alzheimer's disease
EP0787802A3 (https=)
DE3855527D1 (de) Doppelsträngige RNS zur Korrektur von Abnormalitäten von zirkulierenden Immunkomplexen und der Monozytenfunktion
AU8091787A (en) The use of paroxetine to treat pain
SG33992G (en) Binding-inducing composition
PH23901A (en) Treatment of diabetes using fluoxetine
AU7426487A (en) Method of treating depression using d-fenfluramine
ATE22655T1 (de) Infusionsloesungen zur herztherapie.
AU2158688A (en) Use of bezafibrate for treating diabetes
EP0266993A3 (en) Method and therapeutic compositions for the treatment of bleeding disorders
TW217382B (https=)
DE3877102D1 (de) Methode fuer die behandlung von viraler gehirnentzuendung.
DE3685988D1 (de) Verwendung von "naftidrofuryl" zur behandlung von neuropathien.
AU7931487A (en) Therapeutic treatment of abnormal cell growth with follicle regulatory protein
ATE56360T1 (de) Zusammensetzung zur herstellung eines arzneimittels zur therapeutischen behandlung von hauttrauma.